Sugen LLC
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sugen LLC
Mogrify: Using Big Data To Transform Development Of Cell Therapies
Money in the bank, biotech legacies onboard, a fresh partnership, an emerging internal cell therapy pipeline and a grand vision for the broad-scale application of its technology – has Mogrify got it all? The biotech’s chief business officer, Karin Schmitt, talks to In Vivo about the group’s near- and long-term goals.
Chastened Innate Returns Lumoxiti Rights To AZ
The French firm gave back the rights to Lumoxiti on the same day the drug got a thumbs up from the CHMP after struggling to market the rare leukemia drug in the US.
Early EU Approval Wins In Line For Daiichi/AZ & Lilly
Advanced breast cancer treatment Enhertu and non-small cell lung cancer and thyroid cancer therapy Retsevmo are set to win conditional marketing authorizations in the EU shortly. The two drugs are among a number of new products that the European Medicines Agency has just recommended for approval.
Raft Of New Drugs To Learn EU Marketing Fate
ViiV Healthcare’s “last resort” HIV drug, fostemsavir, is one of 16 new medicines that are up for an opinion by the European Medicines Agency on whether they should be authorized for use across the EU.